Millennium Group Intl Bolsa (NASDAQ: MGIH)

Últimas noticias sobre Millennium Group Intl (NASDAQ:MGIH) Bolsa

Millennium Group Intl

Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.

EVAX

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Millennium Group International Holdings Limited - Ordinary Shares

Millennium Group International Holdings Ltd

Barclays analyst Ramsey El-Assal downgrades AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Overweight to Equal-Weight and lowers the price target from $13 to $8.

News

Downgrades

Price Target

Analyst Ratings

AVDX

Barclays Downgrades AvidXchange Holdings to Equal-Weight, Lowers Price Target to $8

On Tuesday, BioHarvest Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) published ‘in vitro' test results for its new olive cell compound, which can reduce fat accumulation in human liver cells.
BioHarvest demonstrated that its novel olive cell compound mitigated fat accumulation in human liver cells, both in a liver steatosis model and in experimental liver fibrosis models.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42431837/exclusive-bioharvest-collaborate-with-tate-lyle-to-develop-proprietary-plant-based-molecules" rel="noreferrer noopener">EXCLUSIVE: BioHarvest Collaborates With Tate &amp; Lyle To Develop Proprietary Plant-Based Molecules</a>
The company attributes the reduction of fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for various effects on the liver) in BioHarvest's Olive cell compound.
Based on these results and additional studies to be conducted in 2025, the company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its contract development and production organization (CDMO) model.
The Olive product will join VINIA as part of the company's portfolio. VINIA, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow.
The company recently announced that VINIA had surpassed $50 million in sales, with over 50,000 active subscribers.
BioHarvest plans to support future growth by expanding its production capacity by 4x and building a new 100-ton-per-year production facility, which is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/43780365/bioharvest-announces-sales-of-flagship-product-vinia-now-exceed-50-million-usd" rel="noreferrer noopener">operational in late 2026</a>.
Price Action: BHST stock closed at $5.03 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44103926/grocery-giant-albertsons-names-susan-morris-as-new-ceo" target="_blank" rel="noreferrer noopener">Grocery Giant Albertsons Names Susan Morris As New CEO</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

General

BHST

EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

<a href="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions" title="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions">https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions</a>

Biotech

Johnson & Johnson MedTech Says 'Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform In U.S. To Transform Treatment Of Difficult-To-Cross Calcified Lesions'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Markets

MARA

MARA Holdings February Bitcoin Product 706 Down From 750 MoM

EXCLUSIVE: BioHarvest Tells Benzinga 'In Vitro Testing of First Lab-Grown Plant-Based Molecules Proves Reduced Fat Accumulation in Liver Cells'

EXCLUSIVE: BioHarvest Tells Benzinga Co. Shows First Synthetic Olive Cells A Capable New Weapon In Fight Against Liver Disease

Parent Company Discusses Strategy to Evolve into a Broader Holding Company with a Focus on Emerging Technologies
NEW YORK, March 4, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>)&nbsp;(the "Company") today announced that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"),&nbsp;has received approval for its Continuing Membership Application ("CMA") from the Financial Industry Regulatory Authority ("FINRA"). The Company also provided additional commentary regarding its plans to develop into a broader holding company with a focus on emerging technologies.

DOMH

Dominari Securities Receives FINRA Approval For Its CMA To Expand Operations

WIIM

BeiGene shares are trading higher after the company announced FDA approval of Tevimbra/chemotherapy combination.

On March 3, 2025, iCoreConnect, Inc. (the "Company") entered into warrant cancellation agreements with the holders of warrant to purchase an aggregate of 142,690 shares of common stock. The canceled warrants included anti-dilution provisions that could have led to an increase in the number of warrants and a reduction in the exercise price if new shares were issued by the Company at a lower price.
 &nbsp;

ICCT

iCoreConnect On Mar. 3 Entered Into Warrant Cancellation Agreements With The Holders Of Warrant To Purchase An Aggregate Of 142,690 Shares Of Common Stock

Tiziana Life Sciences, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company's commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis (ALS) which is supported by the ALS Association.
This IND filing follows the prestigious award of a grant as part of the Hoffman ALS Clinical Trial Awards Program from the ALS Association. Tiziana's intranasal foralumab development programs are now focused on 3 neurodegenerative diseases. ALS, Multiple Sclerosis, and Alzheimer's disease. This grant provides a framework for industry-academia collaboration where new discoveries are translated to clinical studies through innovative research and development.
ALS, also known as Lou Gehrig's disease is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its clinical course can be rapid with marked disability even at an early stage. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Despite its devastating impact, treatment options remain limited, highlighting the critical importance of advancing research efforts like those undertaken by Tiziana Life Sciences.
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant. This filing represents a significant achievement for our team and underscores our commitment to addressing the urgent medical needs of ALS patients."
Upon FDA clearance of the IND application, Tiziana plans to commence a 20-patient clinical trial of two doses of Tiziana's novel and patented therapeutic candidate, intranasal foralumab, aimed at evaluating the safety and early-stage parameters of disease improvement in Amyotrophic Lateral Sclerosis (ALS). The company remains dedicated to delivering innovative solutions that can potentially improve outcomes and quality of life for ALS patients worldwide.

TLSA

Tiziana Life Sciences Announces Investigational New Drug Application Submission For Phase 2 Trial Of Intranasal Foralumab In ALS, Supported By ALS Association

- STAR-1 topline results expected by the end of March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year -
- XYNGARI&#x2122; Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S.&nbsp; and Latin America -

DRMA

Dermata Announced Last Patient Completed Last Visit In XYNGARI Phase 3 STAR-1 Clinical Trial For Acne

New controlled study published in&nbsp;Journal of Nutrition and Dietary Supplements highlights statistically significant reductions in ethanol levels following acute alcohol intake
SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or the "Company"), a wellness and dietary supplement company, today announces the peer-reviewed publication of its groundbreaking randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of Safety Shot&#xAE; in mitigating the negative effects of alcohol consumption. The study, published in the Journal of Nutrition and Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62), demonstrates that Safety Shot&#xAE; statistically significantly reduces blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms compared to placebo (p &lt; 0.05), and at a remarkably faster rate than the body's natural processes. For the complete article, visit the website at: <a href="https://www.globenewswire.com/Tracker?data=WMrB5FCJ7spqdDFaiGgaOalIPHMLw7p7IOTyw0oAzKQ3WxqFYU0LFhPAP0b-gLXh5BNsAX0_KrPK6x9IyWGObFFPAF2q9v4zTdH-7dHHILiW1TDVIt0rcNZlwME-V15r">https://doi.org/10.2147/NDS.S507571</a>

SHOT

Safety Shot Announces First Peer-Reviewed Publication Of Human Clinical Trial Confirming Rapid Alcohol Reduction And Hangover Prevention Published In The Journal Of Nutrition And Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62)

Mizuho analyst Vijay Rakesh maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Outperform and raises the price target from $58 to $68.

MCHP

Mizuho Maintains Outperform on Microchip Technology, Raises Price Target to $68

MASS

908 Devices shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Management

BCRX

BioCryst Pharmaceuticals' CFO Anthony Doyle Notified The Company Of His Intention To Resign From His Employment With The Company, Effective April 9, 2025

ALZN

Alzamend Neuro Plans To Initiate Phase II Study Of AL001 In Bipolar Disorder, Expected To Commence In Q3

&nbsp;ServiceNow and DXC expand their strategic partnership to combine DXC's industry-leading software and expertise with ServiceNow's AI-enabled platform
ASHBURN, Va. and SANTA CLARA, Calif., March 4, 2025 /PRNewswire/ -&nbsp;DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>), a leading Fortune 500 global technology services provider, today announced new offerings with ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), the AI platform for business transformation, to modernize the insurance industry. As an Elite partner, DXC is combining its <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4374637-1&amp;h=7510929&amp;u=https%3A%2F%2Fdxc.com%2Fus%2Fen%2Fabout-us%2Fawards-and-recognition%2Fdxc-technology-is-recognized-by-everest-group-as-the-leading-life-and-annuities-insurance-technology-provider-is-everest-groups-inaugural-ranking&amp;a=industry-leading+solutions">industry-leading solutions</a>&nbsp;and ServiceNow's AI capabilities&nbsp;and workflows&nbsp;to introduce DXC Assure BPM (Business Process Management) powered by ServiceNow.
Today's insurers are&nbsp;pressured to accelerate growth and innovation, streamline operations, and provide faster, more reliable services to policyholders, but are often constrained by processes and workflows that are complex and highly manual. According to HFS&nbsp;Research, 45% of insurers are already investing in technology-driven alignment of their front, middle, and back offices.
DXC and ServiceNow are uniquely positioned to help insurers drive innovation for greater operational efficiency.&nbsp;&nbsp;Combining DXC's insurance expertise and scale with ServiceNow's single platform and data model, DXC Assure BPM powered by ServiceNow integrates AI, data and workflows to reduce process debt, enhance operational efficiency, and improve customer satisfaction. The solution applies across the entire policy lifecycle and is expected to help reduce up to 40% of operational costs typically spent on manual processing.

DXC And ServiceNow Announce New Offerings To Drive AI-Powered Innovation For The Insurance Industry

Contracts

UAVS

AgEagle Aerial Systems Fulfilled Previously Announced Order For 60 RedEdge-P Multispectral Sensors

BOOM

DynaEnergetics Announces It Will Institute A Tariff Surcharge Ranging From 7% To 9% On All Perforating Systems Sold in North America, Effective April 5, 2025. The Surcharge Is Being Implemented In Response To Higher Raw Material Costs Resulting From U.S. Tariffs

ILMN

Illumina shares are trading lower after China banned its gene sequencer imports.

Comments

Millennium Group Intl

Noticias

Últimas noticias sobre Millennium Group Intl (NASDAQ:MGIH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL